June 09, 2020
Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, has announced the pricing of an underwritten public offering of 7,590,909 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 909,091 shares of its common stock at an exercise price of US$0.001 per share. The public offering price of each share of common stock is US$5.50 and the public offering price of each pre-funded warrant is US$5.499 per underlying share. In addition, Kezar has granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock.
Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by Orange County partner Shayne Kennedy and Bay Area partner Brian Cuneo, with San Diego associate Alisa Lalana. Advice was also provided on regulatory matters by Washington, D.C. partner John Manthei and Bay Area counsel Betty Pang, with San Diego associate Amy Speros, and Washington, D.C. associate Barrett Tenbarge; and on intellectual property matters by Bay Area partner Judith Hasko and New York partner Alan Tamarelli, with New York associate Jiqiang Lin.